OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement 
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook 
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
SMC Corp Stock Surges as Palliser Capital Pushes for Major Share Buyback 
Google Secures Pentagon AI Deal for Classified Projects 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal 
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
Nomura Shares Drop After Profit Miss Despite Strong Revenue Growth 
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
Chinese Chip Stocks Surge on AI Boom and Domestic Tech Push 
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
ROSELAND, N.J., May 03, 2017 -- Emisphere Technologies, Inc. (OTCBB:EMIS) announced today that management will host a conference call to discuss the Company's financial and operational results for the first three months ended March 31, 2017, on Friday, May 12, 2017. A press release will be issued prior to market open.
The live webcast of the conference call can be accessed through the Company's web site at www.emisphere.com. The call can also be accessed by dialing (877) 303-9483 (United States and Canada) or (760) 666-3584 (international), and entering Conference ID# 14929495.
In addition, an archive of the webcast can be accessed through the same link and an audio replay of the call will be available beginning Friday, May 12, 2017 at 11:30 AM ET through 11:30 PM ET on May 19, 2017, by calling (855) 859-2056 (United States and Canada) or (404) 537-3406 (International), and entering Conference ID# 14929495.
About Emisphere
Emisphere Technologies is a Drug Delivery Company whose core business strategy is to partner its proprietary drug delivery technology and license Eligen B12. Our thirty year history has made us the established leader in converting injectable therapeutics into advanced oral therapeutics. Utilizing our experience in researching, developing and manufacturing a number of fully characterized carriers in our extensive library, our partners leverage our expertise to employ our unique intracellular delivery mechanism to advance their portfolio and create differentiated line extensions. Our capabilities range from early proof of concept, to extensive development and commercial capabilities.
Emisphere’s technology can enhance the clinical profile of both pre-market and currently marketed products. Further, our broad-based proprietary oral drug delivery platform provides significant increases in bioavailability, facilitates the enhanced absorption of small and large molecules without altering their chemical form, and maintains their biological integrity or pharmacological properties. Finally, it is especially useful for oral delivery of peptides, proteins, oligonucleotides and oligosaccharides. For more information please visit www.emisphere.com.
CONTACT: Alan L. Rubino, CEO 973.532.8000 [email protected]
